(firstQuint)ESPRIT Study in Hypogonadal Men.

 The objective of this study was to evaluate the efficacy and safety of AndroGel (testosterone gel) 1% following administration in community dwelling men with hypogonadism.

 The percent change from baseline to Month 6 in aging male symptom (AMS) assessment was the primary endpoint.

 Secondary endpoints were changes from baseline to Month 6 in International Index of Erectile Dysfunction (IIEF), Multidimensional Fatigue Inventory (MFI), and body mass index (BMI) assessments.

.

 ESPRIT Study in Hypogonadal Men@highlight

Observational study with AndroGel(R), Testosterone 1% gel therapy (ESPRIT) in hypogonadal men in the community over 6 months.

